The effects of off-label Tocilizumab treatment of COVID-19 patients suggested that IL-6 plays a critical role in impairing antigen presentation and antiviral cytotoxicity in severe patients (Ohno et al., 2016; Diao et al., 2020; Mazzoni et al., 2020). Here, IL6 is linked to COVID-19.